In patients with metastatic prostate cancer, lung-only visceral metastases are associated with the best overall survival (OS), whereas other visceral sites portend worse prognoses, a new study finds.

In the study of 1827 patients with metastatic prostate cancer, the median OS time was 22 months. The median OS time was 33 months in patients with lung-only metastases compared with 15 and 16 months among men with liver-only or brain-only metastases, respectively, Stefano Tappero, MD, of the University of Montréal Hospital Center in Canada, and colleagues reported in Clinical Genitourinary Cancer. Men with 2 or more visceral metastatic sites had a median OS time of 15 months.

Among those with lung-only visceral metastases, the investigators observed the highest OS in those with concomitant non-visceral metastases in lymph nodes only (median OS 57 months) compared with lymph nodes and bone (28 months) vs bone only (26 months).

In multivariable Cox regression models, liver-only, brain-only, and 2 or more visceral metastases were significantly associated with 2.1-, 2.1, and 2.0-fold increased risks of all-cause mortality.

The investigators analyzed data from the 2010-2016 Surveillance, Epidemiology and End Results database. Of the 1827 patients, 1044 (57%) had lung-only visceral metastases, 25% liver-only, 7% brain-only, and 11% 2 or more visceral sites. The study lacked detail on the number of metastases at each site, as well as treatment type, dose, and duration.

Prostate Cancer Survival Differs by Site of Visceral Metastases

Want to read more?

Want to read more?